These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 18344568

  • 1. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group.
    N Engl J Med; 2008 Mar 20; 358(12):1215-28. PubMed ID: 18344568
    [Abstract] [Full Text] [Related]

  • 2. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB, Sheikh J, Singh A.
    Curr Med Res Opin; 2010 Aug 20; 26(8):1933-46. PubMed ID: 20565230
    [Abstract] [Full Text] [Related]

  • 3. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
    Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.
    N Engl J Med; 2009 Mar 05; 360(10):985-93. PubMed ID: 19264687
    [Abstract] [Full Text] [Related]

  • 4. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
    Roufosse F, de Lavareille A, Schandené L, Cogan E, Georgelas A, Wagner L, Xi L, Raffeld M, Goldman M, Gleich GJ, Klion A.
    J Allergy Clin Immunol; 2010 Oct 05; 126(4):828-835.e3. PubMed ID: 20810155
    [Abstract] [Full Text] [Related]

  • 5. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Oct 05; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

  • 6. Hypereosinophilic syndrome and mepolizumab.
    Verzegnassi F.
    N Engl J Med; 2008 Jun 26; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
    [No Abstract] [Full Text] [Related]

  • 7. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.
    Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD.
    N Engl J Med; 2019 Apr 04; 380(14):1336-1346. PubMed ID: 30943337
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.
    J Allergy Clin Immunol; 2004 Jan 04; 113(1):115-9. PubMed ID: 14699394
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD.
    J Allergy Clin Immunol; 2013 Feb 04; 131(2):461-7.e1-5. PubMed ID: 23040887
    [Abstract] [Full Text] [Related]

  • 10. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
    Busse WW, Ring J, Huss-Marp J, Kahn JE.
    J Allergy Clin Immunol; 2010 Apr 04; 125(4):803-13. PubMed ID: 20371394
    [Abstract] [Full Text] [Related]

  • 11. [New insights into hypereosinophilic syndromes].
    Bletry O, Kahn JE, Ackermann F, Charles P, Legrand F.
    Bull Acad Natl Med; 2010 Mar 04; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
    [Abstract] [Full Text] [Related]

  • 12. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.
    J Allergy Clin Immunol; 2009 Dec 04; 124(6):1319-25.e3. PubMed ID: 19910029
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
    Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ, HES Mepolizumab study group.
    J Allergy Clin Immunol; 2020 Dec 04; 146(6):1397-1405. PubMed ID: 32956756
    [Abstract] [Full Text] [Related]

  • 14. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.
    Gut; 2010 Jan 04; 59(1):21-30. PubMed ID: 19828470
    [Abstract] [Full Text] [Related]

  • 15. Hypereosinophilic syndrome and mepolizumab.
    Boucher RM, Gilbert-McClain L, Chowdhury B.
    N Engl J Med; 2008 Jun 26; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
    [No Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
    Gleich GJ, Roufosse F, Chupp G, Faguer S, Walz B, Reiter A, Yancey SW, Bentley JH, Steinfeld J, HES Mepolizumab Study Group.
    J Allergy Clin Immunol Pract; 2021 Dec 26; 9(12):4431-4440.e1. PubMed ID: 34389506
    [Abstract] [Full Text] [Related]

  • 17. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ, Tan DC, Yiu RC, How GF.
    Leuk Res; 2008 Jan 26; 32(1):169-71. PubMed ID: 17544504
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, EGPA Mepolizumab Study Team.
    N Engl J Med; 2017 May 18; 376(20):1921-1932. PubMed ID: 28514601
    [Abstract] [Full Text] [Related]

  • 19. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul 18; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 20. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
    Rives S, Alcorta I, Toll T, Tuset E, Estella J, Cross NC.
    J Pediatr Hematol Oncol; 2005 Dec 18; 27(12):663-5. PubMed ID: 16344672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.